Efeitos cardiorrespiratórios da associação de tiletamina/zolazepam em cães (Canis familiaris) pré-tratados ou não pela acepromazina

The aim of this work was to evaluate the use of acepromazine as pre-treatment to tiletamine/zolazepam association. Twenty male and female healthy adult mixed breed dogs were used. The dogs were allocated in two groups of 10 animals each (G1 and G2). To G1 was administered 0.1 ml/kg of saline at 0.9 % (placebo), followed by 10 mg/kg of tiletamine/zolazepam 20 minutes later, both intravenously. Immediately before the pre-anesthetic medication (M1), before the anesthetic’s application (M2) and at 15, 30, 45 and 60 minutes after the administration of tiletamine/zolazepam association (M3 to M6, respectively), measurements of heart rate (HR), systolic, diastolic and mean blood pressures (SBP, DBP e MBP, respectively), cardiac output (CO), cardiac index (CI), systolic volume (SV), electrocardiogram (ECG), respiratory rate (RR), end tidal CO2 (ETCO2), oxihemoglobin saturation (SpO2) and body temperature (T0) were realized. For G2 the same methodology was used, replacing the placebo by acepromazine, at 0.2 mg/kg. The numeric data were submitted to analysis of profile that demonstrated cardiovascular stability and an increase of the anesthetic period with the use of acepromazine, and it was also observed, in G2, that, in spite of the decrease of RR, the SpO2 and ETCO2 values didn’t have significant alterations, allowing to conclude that the use of acepromazine presents advantages in the isolated use of the tiletamine/zolazepam association, in dogs.